The USFDA had conducted an inspection at the facility from 2 to 9 March, 2020.
These test kits have been manufactured in partnership with ICMR-NIV of Pune for surveillance purposes, the company said.
The Nifty Pharma index gained half a percent on May 7, taking gains to around 45 percent since March 23.
The drug will be manufactured at the group’s Ahmedabad facility.
The tablets are indicated for treatment of pulmonary arterial hypertension and will be manufactured at Vapi-based CMO Umedica Laboratories, Cadila Healtcare added.
Local drug companies should address some of the longer term issues concerning the industry such as quality and good manufacturing practices
Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin Tablets, in the strengths of 10 mg and 25 mg (US RLD: Jardiance Tablets), the company said in a filing to the exchanges
The drug will be manufactured at the group’s Ahmedabad SEZ facility.
The drug is for the treatment of schizophrenia and controlling severe nausea and vomiting in adults.
Cadila Healthcare and Ipca Labs are prominent manufacturers of hydroxychloroquine and chloroquine in India. Both are antimalarial drugs.
The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
"Our next strategy is that we want to be IP (intellectual property) driven company and our strong belief has always been that we have to make efforts in research because that's the true disrupter for us," Sharvil Patel said.
Currently Saroglitazar rakes about Rs 50 crore in sales per year, growing at 30 percent
ICICI Direct recommended hold rating on Cadila Healthcare with a target price of Rs 285 in its research report dated February 10, 2020.
The topical manufacturing facility had completed the USFDA audit during December 16-20, 2019.
The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.
Prabhudas Lilladher recommended hold rating on Cadila Healthcare with a target price of Rs 247 in its research report dated February 06, 2020.
CLSA maintained buy rating and raised target to Rs 330 from Rs 310 per share.
Consolidated revenue grew by 1.7 percent year-on-year (up 8 percent QoQ) to Rs 3,638.1 crore in the quarter that ended on December 2019, beating analyst estimates.
United States Food and Drug Administration (USFDA) inspected the manufacturing facility of Alidac Pharmaceuticals, the company's wholly-owned subsidiary, at SEZ, Ahmedabad from January 27 to February 4, 2020, Cadila Healthcare said in a BSE filing.
The United States Food and Drug Administration (USFDA) inspected the company's topical manufacturing facility in Ahmedabad during December 16-20, 2019, the drug firm said in a BSE filing.
Vinglyn and Vinglyn M will be marketed by Zydus Healthcare.